Overview
Investment Stage
Seed; Series A
Portfolio 3
| Date | Name | Website | Total Raised | Location |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| May 19, 2024 | Sudo Biosciences | sudobio.com | $300M | United States, California, Menlo Park |
| Cerevance | cerevance.com | $209.5M | United States |
Persons 16
| Date | First Name | Last Name | Title | Location | |||
| Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Lennart | Spindler | Senior Analyst | |||||
| Luca | Santarelli | Venture Partner | |||||
| Dirk | Landgraf | Principal | |||||
| Barbara | Tate | Venture Partner | |||||
| David | Reynolds | Venture Partner | Sign up to see | ||||
| Christian | Jung | Partner | |||||
| Kate | Bingham | Managing Partner | |||||
| Mike | Ross | Senior Partner | |||||
| Georgia | Frost | Senior Associate |
Show more
Mentions in press and media 10
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 24, 2026 | TRIMTECH Therapeutics Raises $47 Million Seed Funding To Advance Targeted Protein Degradation Portfolio | TRIMTECH Therapeutics announced that it has raised an additional $14 million in seed funding, bringing the total round to $47 million. The additional financing was led by Johnson & Johnson’s corporate venture capital organization, Johns... |
| May 12, 2026 | AstronauTx builds executive team with appointment of experienced clinical development leader Michelle Mellion, MD as Chief Medical Officer | London, UK, 12 May 2026 – AstronauTx Ltd (“AstronauTx”), a biotechnology company developing therapeutics to treat Alzheimer’s Disease and other neurological disorders by improving sleep architecture, announces the appointments of Dr. Michel... |
| Mar 5, 2025 | TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases | Cambridge, UK, 05 March 2025: TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, today announced the closing of its $31 million (£25 million) seed funding ... |
| Feb 13, 2024 | Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M | CARMEL, IN - Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced that during January 2024, it completed a second close of ... |
| Nov 21, 2023 | Dementia Discovery Fund Announces the Acquisition of Caraway Therapeutics by Merck | This transaction highlights DDF’s attractive strategy of investing in novel therapeutics for dementia, a rapidly escalating public health crisis. |
| Oct 9, 2023 | AstronauTx closes a £48 million ($61 million) Series A financing to create new treatments for Alzheimer’s disease | London UK, XXXX– AstronauTx Ltd. (“AstronauTx”), a biotech company developing novel treatments for Alzheimer’s disease and other neurodegenerative disorders today announced the completion of a £48 million ($61 million) Series A financing.... |
| Jun 28, 2023 | Renowned Neuroscientist Prof. Michael Heneka, M.D, Joins The Dementia Discovery Fund (DDF) as Scientific Advisor | Boston, MA (US) and London (UK) –June 28th 2023. The Dementia Discovery Fund (DDF), the world’s largest family of specialized venture capital funds dedicated to investing in novel treatments for neurodegenerative disorders causing dementia,... |
| May 31, 2023 | Violet Therapeutics raises $10.6 million in seed funding led by the Dementia Discovery Fund (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) and Mass General Brigham Ventures (MGBV) | Round led by the DDF (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) and founding investor Mass General Brigham Ventures (MGBV), and joined by Ono Venture Investment |
| Dec 13, 2022 | Dementia Discovery Fund invests in Amphista Therapeutics as it targets neurodegenerative diseases | Cambridge, UK – December 13, 2022 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced a Series B extension investment by the Dementia Discovery Fund (DDF). The investment is in... |
Reviews 0
FAQ about Dementia Discovery Fund
How many startups has Dementia Discovery Fund invested in?
Dementia Discovery Fund has 3 portfolio companies on Parsers VC, among them Sudo Biosciences and Cerevance.
What has the press written about Dementia Discovery Fund?
Parsers VC has collected 10 articles mentioning Dementia Discovery Fund, among them “TRIMTECH Therapeutics Raises $47 Million Seed Funding To Advance Targeted Protein Degradation Portfolio” (Jun 24, 2026) and “AstronauTx builds executive team with appointment of experienced clinical development leader Michelle Mellion, MD as Chief Medical Officer” (May 12, 2026).
Is Dementia Discovery Fund still active?
Yes, Dementia Discovery Fund is active; its latest activity on Parsers VC dates from Aug 17, 2026.